Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine

During primary angioplasty, abciximab enhances myocardial reperfusion, translating into a reduced incidence of 6-month left ventricular remodeling. In contrast, adenosine administration improves angiographic results but does not prevent left ventricular remodeling.